Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Burlington Stores Inc (BURL) vs ClearPoint Neuro Inc (CLPT) Price & Performance

Burlington Stores IncTrade
ClearPoint Neuro IncTrade

Price performance (Past 24H)

Key statistics

Burlington Stores Inc vs ClearPoint Neuro Inc — how do they compare? Burlington Stores Inc trades at $351.97 (market cap $22.59B), while ClearPoint Neuro Inc trades at $15.2 (market cap $454.21M). The key difference: Burlington Stores Inc is far larger — about 49.7× ClearPoint Neuro Inc's market cap, and Burlington Stores Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.

BURLCLPT
Market Cap
$22.59B$454.21M
Sector
Consumer CyclicalHealth
52-Week High
$372.19$29.60
52-Week Low
$242.43$8.66
Enterprise Value
$27.71B$488.79M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Burlington Stores Inc

Burlington Stores (BURL) trades at $353.4, down 4.87% over 24 hours but near its 52-week high, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.01 exceeding expectations. Revenue grew to $10.63 billion in 2025, and the smaller-store strategy is boosting sales productivity. Analyst consensus is overwhelmingly positive, with 94% buy ratings and a $367 price target.

Outlook remains favorable due to consistent earnings outperformance and growth initiatives, though risks include high valuation multiples and competitive retail pressures. The stock offers upside potential aligned with analyst targets, but investors should monitor execution on expansion and margin sustainability.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.

The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.

Returns comparison

Trailing returns across standard periods

About Burlington Stores Inc

Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.

Read more on BURL

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT